A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin

Potential new therapy for ovarian clear cell adenocarcinoma

Sachiko Ezawa, Nao Suzuki, Shinji Ohie, Atsushi Higashiguchi, Fumihito Hosoi, Kenji Kitazato, Nobuyuki Susumu, Daisuke Aoki

Research output: Contribution to journalArticle

Abstract

Objective.: A novel retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), induces apoptosis of ovarian clear cell adenocarcinoma. The antitumor effect of TAC-101 alone or combined with cisplatin was tested using human ovarian carcinoma. Methods.: Induction of genes related to apoptosis by TAC-101 or cisplatin was assessed by DNA microarray analysis. TAC-101 (8 mg/kg/day orally for 21 days), cisplatin (7 mg/kg intravenously on day 1), or a combination of both drugs at the same dosages was administered to nude mice implanted subcutaneously with RMG-I or RMG-II clear cell adenocarcinoma cells. The antitumor effect was evaluated by calculating the treated/control tumor volume ratio at 21 days after implantation. The histoculture drug response assay was also performed using fresh surgical specimens of human ovarian cancer to determine the 50% inhibitory concentration (IC50). Results.: Different apoptosis-related genes were induced by TAC-101 and cisplatin. Compared with control mice, the volume of both RMG-I and RMG-II tumors was significantly reduced (p < 0.05) by either drug. The IC50 values of cisplatin and TAC-101 showed a significant correlation (p < 0.01). Conclusion.: These in vitro findings suggest that a combination of TAC-101 and cisplatin may be a potential new treatment for ovarian clear cell adenocarcinoma.

Original languageEnglish
Pages (from-to)627-631
Number of pages5
JournalGynecologic Oncology
Volume108
DOIs
Publication statusPublished - 2008 Mar

Fingerprint

Clear Cell Adenocarcinoma
Retinoids
Cisplatin
Inhibitory Concentration 50
Therapeutics
Apoptosis
TAC 101
Drug Combinations
Microarray Analysis
Oligonucleotide Array Sequence Analysis
Tumor Burden
Nude Mice
Pharmaceutical Preparations
Ovarian Neoplasms
Genes
Carcinoma

Keywords

  • Cisplatin
  • Clear cell adenocarcinoma
  • Histoculture drug response assay
  • Ovarian carcinoma
  • TAC-101

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin : Potential new therapy for ovarian clear cell adenocarcinoma. / Ezawa, Sachiko; Suzuki, Nao; Ohie, Shinji; Higashiguchi, Atsushi; Hosoi, Fumihito; Kitazato, Kenji; Susumu, Nobuyuki; Aoki, Daisuke.

In: Gynecologic Oncology, Vol. 108, 03.2008, p. 627-631.

Research output: Contribution to journalArticle

Ezawa, Sachiko ; Suzuki, Nao ; Ohie, Shinji ; Higashiguchi, Atsushi ; Hosoi, Fumihito ; Kitazato, Kenji ; Susumu, Nobuyuki ; Aoki, Daisuke. / A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin : Potential new therapy for ovarian clear cell adenocarcinoma. In: Gynecologic Oncology. 2008 ; Vol. 108. pp. 627-631.
@article{6876322aebb842f0a4a79f524708cf77,
title = "A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin: Potential new therapy for ovarian clear cell adenocarcinoma",
abstract = "Objective.: A novel retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), induces apoptosis of ovarian clear cell adenocarcinoma. The antitumor effect of TAC-101 alone or combined with cisplatin was tested using human ovarian carcinoma. Methods.: Induction of genes related to apoptosis by TAC-101 or cisplatin was assessed by DNA microarray analysis. TAC-101 (8 mg/kg/day orally for 21 days), cisplatin (7 mg/kg intravenously on day 1), or a combination of both drugs at the same dosages was administered to nude mice implanted subcutaneously with RMG-I or RMG-II clear cell adenocarcinoma cells. The antitumor effect was evaluated by calculating the treated/control tumor volume ratio at 21 days after implantation. The histoculture drug response assay was also performed using fresh surgical specimens of human ovarian cancer to determine the 50{\%} inhibitory concentration (IC50). Results.: Different apoptosis-related genes were induced by TAC-101 and cisplatin. Compared with control mice, the volume of both RMG-I and RMG-II tumors was significantly reduced (p < 0.05) by either drug. The IC50 values of cisplatin and TAC-101 showed a significant correlation (p < 0.01). Conclusion.: These in vitro findings suggest that a combination of TAC-101 and cisplatin may be a potential new treatment for ovarian clear cell adenocarcinoma.",
keywords = "Cisplatin, Clear cell adenocarcinoma, Histoculture drug response assay, Ovarian carcinoma, TAC-101",
author = "Sachiko Ezawa and Nao Suzuki and Shinji Ohie and Atsushi Higashiguchi and Fumihito Hosoi and Kenji Kitazato and Nobuyuki Susumu and Daisuke Aoki",
year = "2008",
month = "3",
doi = "10.1016/j.ygyno.2007.10.019",
language = "English",
volume = "108",
pages = "627--631",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin

T2 - Potential new therapy for ovarian clear cell adenocarcinoma

AU - Ezawa, Sachiko

AU - Suzuki, Nao

AU - Ohie, Shinji

AU - Higashiguchi, Atsushi

AU - Hosoi, Fumihito

AU - Kitazato, Kenji

AU - Susumu, Nobuyuki

AU - Aoki, Daisuke

PY - 2008/3

Y1 - 2008/3

N2 - Objective.: A novel retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), induces apoptosis of ovarian clear cell adenocarcinoma. The antitumor effect of TAC-101 alone or combined with cisplatin was tested using human ovarian carcinoma. Methods.: Induction of genes related to apoptosis by TAC-101 or cisplatin was assessed by DNA microarray analysis. TAC-101 (8 mg/kg/day orally for 21 days), cisplatin (7 mg/kg intravenously on day 1), or a combination of both drugs at the same dosages was administered to nude mice implanted subcutaneously with RMG-I or RMG-II clear cell adenocarcinoma cells. The antitumor effect was evaluated by calculating the treated/control tumor volume ratio at 21 days after implantation. The histoculture drug response assay was also performed using fresh surgical specimens of human ovarian cancer to determine the 50% inhibitory concentration (IC50). Results.: Different apoptosis-related genes were induced by TAC-101 and cisplatin. Compared with control mice, the volume of both RMG-I and RMG-II tumors was significantly reduced (p < 0.05) by either drug. The IC50 values of cisplatin and TAC-101 showed a significant correlation (p < 0.01). Conclusion.: These in vitro findings suggest that a combination of TAC-101 and cisplatin may be a potential new treatment for ovarian clear cell adenocarcinoma.

AB - Objective.: A novel retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), induces apoptosis of ovarian clear cell adenocarcinoma. The antitumor effect of TAC-101 alone or combined with cisplatin was tested using human ovarian carcinoma. Methods.: Induction of genes related to apoptosis by TAC-101 or cisplatin was assessed by DNA microarray analysis. TAC-101 (8 mg/kg/day orally for 21 days), cisplatin (7 mg/kg intravenously on day 1), or a combination of both drugs at the same dosages was administered to nude mice implanted subcutaneously with RMG-I or RMG-II clear cell adenocarcinoma cells. The antitumor effect was evaluated by calculating the treated/control tumor volume ratio at 21 days after implantation. The histoculture drug response assay was also performed using fresh surgical specimens of human ovarian cancer to determine the 50% inhibitory concentration (IC50). Results.: Different apoptosis-related genes were induced by TAC-101 and cisplatin. Compared with control mice, the volume of both RMG-I and RMG-II tumors was significantly reduced (p < 0.05) by either drug. The IC50 values of cisplatin and TAC-101 showed a significant correlation (p < 0.01). Conclusion.: These in vitro findings suggest that a combination of TAC-101 and cisplatin may be a potential new treatment for ovarian clear cell adenocarcinoma.

KW - Cisplatin

KW - Clear cell adenocarcinoma

KW - Histoculture drug response assay

KW - Ovarian carcinoma

KW - TAC-101

UR - http://www.scopus.com/inward/record.url?scp=39149110643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149110643&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2007.10.019

DO - 10.1016/j.ygyno.2007.10.019

M3 - Article

VL - 108

SP - 627

EP - 631

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

ER -